SCHEMBL20157286

SCHEMBL20157286

CCOC(=O)Cc1c(I)cn(C)c1C#N

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.45
ALDH1A1 P00352 5/20 0.45
HPGD P15428 4/20 0.45
HSD17B10 Q99714 3/20 0.45
CYP2C9 P11712 2/20 0.44
KMT2A Q03164 1/20 0.39
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 5/20 0.36
TDP1 Q9NUW8 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HTT P42858 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 2/20 0.35
TNF P01375 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20157331 0.86 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10CYP2C9
SCHEMBL21351994 0.75 RAD52 (0.35) ALDH1A1
SCHEMBL20157280 0.71 KDM4E (0.46) KDM4EALDH1A1HPGDHSD17B10CYP2C9
SCHEMBL20157812 0.69 BRD4 (0.35) KDM4EALDH1A1HPGDHSD17B10CYP2C9
SCHEMBL25664507 0.67 GAA (0.57) KDM4EALDH1A1HSD17B10KMT2AL3MBTL1
SCHEMBL20157786 0.65 KDM4E (0.48) KDM4EALDH1A1HPGDHSD17B10CYP2C9
SCHEMBL2774909 0.64 KDM4E (0.40) KDM4EALDH1A1HPGDHSD17B10CYP2C9
SCHEMBL24440125 0.64 GAA (0.40) KDM4EALDH1A1HPGDHSD17B10KMT2A
SCHEMBL29122112 0.63 NLRP3 (0.48) KDM4EALDH1A1HPGDHSD17B10CYP2C9
SCHEMBL4383554 0.63 KDM4E (0.48) KDM4EALDH1A1HPGDHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed
WO-2018086605-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 山东罗欣药业集团股份有限公司 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 KDM4E 2994/4885ALDH1A1 4457/4885HPGD 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.